Aytu Biopharma, Inc. · NASDAQ:AYTU
Aytu Biopharma — IPO Roadshow (June 2023)
27 slides from Aytu Biopharma's IPO roadshow presentation, Jun 6, 2023
Slide 1: Aytu BioPharma, Inc. June 2023
Aytu BioPharma, Inc. Nasdaq: AYTU June 2023
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation includes forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amende d, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. All statements other than statements of historical facts conta
Slide 3: Strong Revenue Growth, Positive Adjusted EBITDA for Rx Segment
Strong Revenue Growth Positive Adjusted EBITDA for Rx Segment Market Dynamics and Company Growth Drivers • YTD FY 2023 (Mar) total net revenue increased 10.8% to $76.7 million from $69.2 million in year ago period. • FY 2022 (Jun) total net revenue increased 47% to $96.7 million from $65.6 million i
Slide 4: Strong Revenue Growth
Strong Revenue Growth June 30 Fiscal Year - End $17.2 $32.7 $61.1 $10.4 $33.0 $35.5 $0 $10 $20 $30 $40 $50 $60 $70 $80 $90 $100 2020 2021 2022 Prescription Consumer Health Revenue $27.6 $65.6 $96.7 $ in Millions 4
Slide 5: Strategic Realignment to Focus on Commercial Operations
Strategic Realignment to Focus on Commercial Operations o YTD 2023 (Q3 Mar. 2023) Rx Adjusted EBITDA was positive $1.1M o On October 13th, 2022, Aytu announced a strategic shift to focus corporate resources on commercial operations and indefinitely suspended all clinical development programs. o This
Slide 6: Aytu BioPharma's Value Drivers
Aytu BioPharma’s Value Drivers Growth Drivers • Rapid prescription & revenue growth driven by organic growth and acquisitions • Overall net revenue from prescription products was $61.1 million in FY 2022, compared to $32.7 million in the prior year period, growth of 87%. • ADHD products grew 294% Yo
Slide 7: Rx Segment Overview
Therapeutic Areas Rx Segment Overview
Slide 8: Differentiated Rx Brands Focused on ADHD & Pediatrics
Multi - vitamin + fluoride supplement line containing novel L - methylfolate • Most prescribed multivitamin + fluoride Rx brand in U.S. • Provides a convenient, child friendly supplement for patients in non - fluoridated areas • Only fluoride supplement containing Arcofolin ®, a ‘body ready’ L - met
Slide 9: Rx Segment
Rx Segment $10.9 $42.9 $31.0 $8.4 $12.4 $16.1 $18.2 $8.9 $9.4 $2.2 $1.4 $0 $10 $20 $30 $40 $50 $60 $70 2020 2021 2022 YTD 2023 (Mar) ADHD Pediatric Other $ Million ($12.5) ($25.5) ($5.5) $1.1 ($30) ($25) ($20) ($15) ($10) ($5) $0 $5 2020 2021 2022 YTD 2023 (Mar) $ Million Revenue Adjusted EBITDA Pos
Slide 10: ADHD Market Dynamics
ADHD Market Dynamics o Adzenys XR - ODT is FDA - approved as bioequivalent to Adderall XR and is the first and only orally disintegrating tablet (ODT) extended - release amphetamine. ODTs have a rapid onset, are easy to take, and help caregivers prevent “ cheeking ” or patient non - use of ADHD medi
Slide 11: Fluoride Market Dynamics
Fluoride Market Dynamics o Poly - Vi - Flor ® and Tri - Vi - Flor ® are two complementary prescription fluoride - based supplement product lines containing combinations of multiple vitamins and sodium fluoride in various oral formulations. o While a majority (63.4%) of US drinking water is fluoridat
Slide 12: Strong Prescription Growth Across Portfolio
Strong Prescription Growth Across Portfolio Since FY 2020, the total prescriptions written monthly for both ADHD and Pediatric products have essentially doubled, supporting revenue trends. 12 0 2,000 4,000 6,000 8,000 10,000 12,000 14,000 16,000 0 5,000 10,000 15,000 20,000 25,000 30,000 35,000 40,0
Slide 13: Aytu RxConnect Driving Rx Growth
Aytu RxConnect Driving Rx Growth o ~1,000 pharmacies nationwide including independent pharmacies and two regional grocery chains o Offers prescribers and patients affordability, predictability and access to Aytu brands for 100% of commercially insured o Reduces pharmacy call backs relating to prior
Slide 14: Rx Segment Outlook
o Future growth and profitability improvements driven by: o ADHD market growth of approximately high single digits per year o Tailwinds from ongoing amphetamine and methylphenidate supply disruptions o Efficient salesforce that is making more consistent strides with overall targeting and improvement
Slide 15: The Aytu RxConnect Platform Delivers Value for Patients, Prescribers, and Aytu
The Aytu RxConnect Platform Delivers Value for Patients, Prescribers, and Aytu % Core Products TRx through RxConnect Pharmacies 41% Reduction in Patient Out - of - Pocket Cost 2x Improvement in Aytu per Rx Contribution Margin 36% Increase in Rx Refills 15 79% 82% 82% 83% 87% 88% 90% 91% 91% 91% 91%
Slide 16: Consumer Health Segment Overview
Therapeutic Areas Consumer Health Segment Overview
Slide 17: Branded, Value-Based Consumer Health Products
Branded, Value - Based Consumer Health Products Regoxidine ® Men's 5% Minoxidil Topical Foam, USP, Hair Regrowth Treatment • Regoxidine ® Men's Hair Loss Foam is a proprietary over - the - counter topical that works to treat hair loss in men. • Value brand competing with Rogaine® OmepraCareDR ® Hear
Slide 18: Financial Summary
Therapeutic Areas Financial Summary
Slide 19: Revenue
Revenue $ Million $ Million 47% YoY growth in Revenue driven by strength in Rx segment (87% YoY growth) Annual Year - to - Date June 30 Fiscal Year - End June 30 Fiscal Year - End $17.2 $32.7 $61.1 $10.4 $33.0 $35.5 $0 $10 $20 $30 $40 $50 $60 $70 $80 $90 $100 2020 2021 2022 Prescription Consumer Hea
Slide 20: Adjusted EBITDA
Adjusted EBITDA $ Million $ Million Aytu generated positive Adjusted EBITDA during 2 of its 3 quarters in FY 2023 Annual Year - to - Date June 30 Fiscal Year - End June 30 Fiscal Year - End ($15.2) ($34.8) ($21.5) ($40) ($35) ($30) ($25) ($20) ($15) ($10) ($5) $0 2020 2021 2022 ($17.6) ($4.4) ($20)
Slide 21: Quarterly Operating Expense
Quarterly Operating Expense (excludes impairment and amortization of intangibles assets)` $0.8 $0.3 $0.3 $0.4 $0.3 $0.2 $0.4 $0.5 $12.2 $9.3 $9.7 $9.7 $10.0 $10.1 $10.6 $12.8 $8.6 $8.2 $8.0 $7.6 $7.4 $7.3 $8.0 $7.2 $3.5 $1.4 $4.2 $2.9 $3.0 $0.9 $1.3 $0.4 $0 $2 $4 $6 $8 $10 $12 $14 Q421 Q122 Q222 Q32
Slide 22: Balance Sheet Highlights
Balance Sheet Highlights (in thousands except shares outstanding) 3/31/2023 Cash and cash equivalents $19,179 Total current assets $78,465 Intangible assets, net $63,464 Goodwill $0 Total assets $147,216 Total current liabilities $85,416 Debt, net of current portion $11,386 Total liabilities $106,30
Slide 23: Investment Highlights
Investment Highlights o Strong revenue growth over past 3 years driven by organic growth and strategic acquisitions driving $100M+ annualized run rate o Company generated positive adjusted EBITDA in 2 of 3 Fiscal 2023 quarters o Positive industry dynamics in primary prescription markets (ADHD and Fl
Slide 24: Appendix
Therapeutic Areas Appendix
Slide 25: Adjusted EBITDA Reconciliation
Adjusted EBITDA Reconciliation 25
Slide 26: Adjusted EBITDA Reconciliation (Rx)
Adjusted EBITDA Reconciliation (Rx) 26
Slide 27: Adjusted EBITDA Reconciliation (Consumer Health)
Adjusted EBITDA Reconciliation (Consumer Health) 27